CAMP4 Therapeutics (NASDAQ:CAMP) Director Andrew Schwab Sells 114,700 Shares of Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 114,700 shares of CAMP4 Therapeutics stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $4.54, for a total value of $520,738.00. Following the completion of the transaction, the director owned 2,465,298 shares in the company, valued at $11,192,452.92. This represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

CAMP4 Therapeutics Trading Up 0.4%

Shares of CAMP traded up $0.02 during trading hours on Friday, hitting $4.48. The company had a trading volume of 126,663 shares, compared to its average volume of 183,971. The company has a market capitalization of $281.12 million, a PE ratio of -1.93 and a beta of 0.22. CAMP4 Therapeutics Corporation has a one year low of $1.41 and a one year high of $7.75. The company’s fifty day moving average price is $4.11 and its two-hundred day moving average price is $4.33.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The company had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. Analysts forecast that CAMP4 Therapeutics Corporation will post -0.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CAMP. UBS Group set a $15.00 price objective on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Piper Sandler reissued an “overweight” rating and set a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Finally, Weiss Ratings upgraded CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.56.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Bridgeway Capital Management LLC purchased a new stake in shares of CAMP4 Therapeutics during the second quarter valued at $36,000. China Universal Asset Management Co. Ltd. purchased a new position in CAMP4 Therapeutics in the 4th quarter worth $61,000. Jefferies Financial Group Inc. acquired a new stake in CAMP4 Therapeutics during the 4th quarter worth about $70,000. Bank of America Corp DE acquired a new stake in CAMP4 Therapeutics during the 2nd quarter worth about $78,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in CAMP4 Therapeutics during the 4th quarter valued at about $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.